ciprofloxacin has been researched along with ambroxol in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Bao, L; Lu, Q; Ran, T; Yu, J; Zhong, H | 1 |
Cheng, C; Du, L; He, Y; Lu, Q; Ran, T; Yu, J | 1 |
He, Y; Li, F; Wang, W; Wang, Z; Yu, J | 1 |
4 other study(ies) available for ciprofloxacin and ambroxol
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model.
Topics: Ambroxol; Animals; Anti-Bacterial Agents; Biofilms; Catheters; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Intubation, Intratracheal; Lung; Microscopy, Electron, Scanning; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Respiratory Tract Infections | 2013 |
Ciprofloxacin plus erythromycin or ambroxol ameliorates endotracheal tube-associated Pseudomonas aeruginosa biofilms in a rat model.
Topics: Ambroxol; Animals; Anti-Bacterial Agents; Biofilms; Catheters, Indwelling; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Erythromycin; Female; Male; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Respiration, Artificial | 2015 |
Ambroxol inhibits mucoid conversion of Pseudomonas aeruginosa and contributes to the bactericidal activity of ciprofloxacin against mucoid P. aeruginosa biofilms.
Topics: Ambroxol; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Synergism; Expectorants; Humans; Hydrogen Peroxide; Infant, Newborn; Microbial Viability; Polysaccharides, Bacterial; Pseudomonas aeruginosa; Topoisomerase II Inhibitors | 2016 |